142 related articles for article (PubMed ID: 38297928)
1. Predictors of Psoriasis Area and Severity Index 100 response in Korean patients with moderate-to-severe plaque psoriasis receiving biologics.
Kim TR; Won Y; Kim Y; Won SH; Bae KN; Lee J; Shin K; Kim H; Ko H; Kim MB; Kim B
Eur J Dermatol; 2023 Oct; 33(5):518-523. PubMed ID: 38297928
[TBL] [Abstract][Full Text] [Related]
2. Complete skin clearance and Psoriasis Area and Severity Index response rates in clinical practice: predictors, health-related quality of life improvements and implications for treatment goals.
Norlin JM; Nilsson K; Persson U; Schmitt-Egenolf M
Br J Dermatol; 2020 Apr; 182(4):965-973. PubMed ID: 31325318
[TBL] [Abstract][Full Text] [Related]
3. PACE study: real-life Psoriasis Area and Severity Index (PASI) 100 response with biological agents in moderate-severe psoriasis.
Carrera CG; Dapavo P; Malagoli P; Naldi L; Arancio L; Gaiani F; Egan CG; Di Mercurio M; Cattaneo A
J Dermatolog Treat; 2018 Aug; 29(5):481-486. PubMed ID: 29058948
[TBL] [Abstract][Full Text] [Related]
4. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E; Chaimani A; Garcia-Doval I; Doney L; Dressler C; Hua C; Hughes C; Naldi L; Afach S; Le Cleach L
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD011535. PubMed ID: 33871055
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of secukinumab as first biologic treatment, compared with other biologics, for moderate to severe psoriasis in Germany.
Augustin M; McBride D; Gilloteau I; O'Neill C; Neidhardt K; Graham CN
J Eur Acad Dermatol Venereol; 2018 Dec; 32(12):2191-2199. PubMed ID: 29729105
[TBL] [Abstract][Full Text] [Related]
6. Clinical implications and predictive values of early PASI responses to tildrakizumab in patients with moderate-to-severe plaque psoriasis.
Feldman SR; Merola JF; Pariser DM; Zhang J; Zhao Y; Mendelsohn AM; Gottlieb AB
J Dermatolog Treat; 2022 May; 33(3):1670-1675. PubMed ID: 33678106
[TBL] [Abstract][Full Text] [Related]
7. A Comparison of Psoriasis Severity in Pediatric Patients Treated With Methotrexate vs Biologic Agents.
Bronckers IMGJ; Paller AS; West DP; Lara-Corrales I; Tollefson MM; Tom WL; Hogeling M; Belazarian L; Zachariae C; Mahé E; Siegfried E; Blume-Peytavi U; Szalai Z; Vleugels RA; Holland K; Murphy R; Puig L; Cordoro KM; Lambert J; Alexopoulos A; Mrowietz U; Kievit W; Seyger MMB;
JAMA Dermatol; 2020 Apr; 156(4):384-392. PubMed ID: 32022846
[TBL] [Abstract][Full Text] [Related]
8. Frequency and predictors of a high clinical response in patients with psoriasis on biological therapy in daily practice: results from the prospective, multicenter BioCAPTURE cohort.
Zweegers J; Roosenboom B; van de Kerkhof PC; van den Reek JM; Otero ME; Atalay S; Kuijpers AL; Koetsier MI; Arnold WP; Berends MA; Weppner-Parren L; Bijen M; Njoo MD; Mommers JM; van Lümig PP; Driessen RJ; Kievit W; de Jong EM
Br J Dermatol; 2017 Mar; 176(3):786-793. PubMed ID: 27454758
[TBL] [Abstract][Full Text] [Related]
9. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E; Chaimani A; Afach S; Doney L; Dressler C; Hua C; Mazaud C; Phan C; Hughes C; Riddle D; Naldi L; Garcia-Doval I; Le Cleach L
Cochrane Database Syst Rev; 2020 Jan; 1(1):CD011535. PubMed ID: 31917873
[TBL] [Abstract][Full Text] [Related]
10. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E; Chaimani A; Guelimi R; Garcia-Doval I; Hua C; Hughes C; Naldi L; Kinberger M; Afach S; Le Cleach L
Cochrane Database Syst Rev; 2023 Jul; 7(7):CD011535. PubMed ID: 37436070
[TBL] [Abstract][Full Text] [Related]
11. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E; Chaimani A; Garcia-Doval I; Doney L; Dressler C; Hua C; Hughes C; Naldi L; Afach S; Le Cleach L
Cochrane Database Syst Rev; 2022 May; 5(5):CD011535. PubMed ID: 35603936
[TBL] [Abstract][Full Text] [Related]
12. Blood Monocyte Count Can Predict Early Response to Secukinumab Therapy in Patients With Psoriasis.
Ziolkowska-Banasik D; Hadas E; Pastuszczak M
J Drugs Dermatol; 2024 Feb; 23(2):74-77. PubMed ID: 38306130
[TBL] [Abstract][Full Text] [Related]
13. Review of the reasons for and effectiveness of switching biologics for psoriasis treatment in Korea.
Shin JO; Shin BS; Bae KN; Shin K; Kim HS; Ko HC; Kim MB; Kim B
Indian J Dermatol Venereol Leprol; 2023; 89(6):928. PubMed ID: 37317715
[TBL] [Abstract][Full Text] [Related]
14. Comparison between super-responders and non-super-responders in psoriasis under adalimumab treatment: a real-life cohort study on the effectiveness and drug survival over one-year.
Liu Y; Hu K; Jian L; Duan Y; Zhang M; Kuang Y
J Dermatolog Treat; 2024 Dec; 35(1):2331782. PubMed ID: 38513258
[TBL] [Abstract][Full Text] [Related]
15. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial.
Reich K; Armstrong AW; Langley RG; Flavin S; Randazzo B; Li S; Hsu MC; Branigan P; Blauvelt A
Lancet; 2019 Sep; 394(10201):831-839. PubMed ID: 31402114
[TBL] [Abstract][Full Text] [Related]
16. Psoriasis treat to target: defining outcomes in psoriasis using data from a real-world, population-based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR).
Mahil SK; Wilson N; Dand N; Reynolds NJ; Griffiths CEM; Emsley R; Marsden A; Evans I; Warren RB; Stocken D; Barker JN; Burden AD; Smith CH;
Br J Dermatol; 2020 May; 182(5):1158-1166. PubMed ID: 31286471
[TBL] [Abstract][Full Text] [Related]
17. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E; Chaimani A; Garcia-Doval I; Do G; Hua C; Mazaud C; Droitcourt C; Hughes C; Ingram JR; Naldi L; Chosidow O; Le Cleach L
Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011535. PubMed ID: 29271481
[TBL] [Abstract][Full Text] [Related]
18. Real-world outcomes in patients with moderate-to-severe plaque psoriasis treated with guselkumab for up to 1 year.
Galluzzo M; Talamonti M; Bernardini N; Chiricozzi A; De Simone C; Bonifati C; Bruni P; Diotallevi F; Esposito M; Graceffa D; Hansel K; Loconsole F; Moretta G; Mugheddu C; Papini M; Richetta A; Skroza N; Atzori L; Fargnoli MC; Persechino S; Offidani A; Stingeni L; Peris K; Potenza C; Bianchi L
Expert Opin Biol Ther; 2022 Dec; 22(12):1585-1592. PubMed ID: 35708257
[TBL] [Abstract][Full Text] [Related]
19. Psoriasis patients' characteristics associated with high PASI response to tildrakizumab: an international dual center study.
Burlando M; Maul JT; Salvi I; Simic D; Cozzani E; Ak M; Birkenmaier I; Parodi A
Eur Rev Med Pharmacol Sci; 2022 Sep; 26(18):6772-6776. PubMed ID: 36196725
[TBL] [Abstract][Full Text] [Related]
20. Secukinumab dosing optimization in patients with moderate-to-severe plaque psoriasis: results from the randomized, open-label OPTIMISE study.
Reich K; Puig L; Szepietowski JC; Paul C; Lacour JP; Tsianakas A; Sieder C; Rissler M; Pournara E; Orsenigo R
Br J Dermatol; 2020 Feb; 182(2):304-315. PubMed ID: 31102257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]